At Ipsen the patient is at the heart of what we do. We continuously invest to innovate and deliver therapeutic solutions for the patient’s benefit.
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, bladder, kidney cancer, pancreatic and breast cancers.
Ipsen continues to develop innovative medicines in rare diseases to address conditions with high unmet needs, with specific investment in pituitary pathologies and growth disorders.
Ipsen is a key player in the treatment of movement disorders. The group is committed to improving the mobility, independence and quality of life of patients with these very disabling disorders. Ipsen’s consolidated expertise in the field of neurotoxins dates back over 25 years.
In Consumer Healthcare, Ipsen offers treatments for gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Ipsen has had a strong presence in international markets in this field for many years.